Involvement of Mediterranean fever gene mutations in colchicine-responsive enterocolitis: a retrospective cohort study Authors: Hiroshi Nakase, Kohei Wagatsuma, Taku Kobayashi, Takayuki Matsumoto, Motohiro Esaki, Kenji Watanabe, Reiko Kunisaki, Teruyuki Takeda, Katsuhiro Arai, Takashi Ibuka, Dai Ishikawa, Yuichi Matsuno, Hirotake Sakuraba, Nobuhiro Ueno, Kaoru Yokoyama, Masayuki Saruta, Ryota Hokari, Junji Yokoyama, Shu Tamano, Masanori Nojima, Tadakazu Hisamatsu, MEFV-IBDU Group Published: 2024 ABSTRACT SummaryBackgroundThe involvement of Mediterranean fever (MEFV) gene mutations in patients with inflammatory bowel disease unclassified (IBDU) remains unclear. This study aimed to determine the clinical characteristics and responsiveness to colchicine in Japanese patients with IBDU carrying MEFV mutations.MethodsIn this retrospective cohort study, we examined MEFV mutations using gene analysis, clinical information, and colchicine responsiveness. Furthermore, we examined cytokine production in exon 2-mutated THP-1 cells (a monocytic cell line) and microbiome analysis.FindingsOf the 396 patients diagnosed with IBDU, 60.1% had MEFV mutations. Exon 2 mutations were the most common (83.7%). Among patients with available clinical information, 43.3% of patients with IBDU had typical Familial Mediterranean fever (FMF). The efficacy of colchicine in patients with IBDU carrying MEFV mutations was 84.6%. Significant differences were noted in the production of inflammatory; cytokines between THP-1 cells with and without MEFV mutations. Microbial compositions differed between patients with IBDU carrying MEFV mutations and patients with IBD and healthy controls.InterpretationPatients with IBDU carrying MEFV mutations responded well to colchicine treatment. A notable subset of patients met the criteria for typical FMF. Alterations in intestinal microbiota may contribute to disease pathogenesis.FundingThis work was supported by the Japan Agency for Medical Research and Development (21ek0410057h0003), a grant from the Uehara Memorial Foundation, and the Health and Labour Sciences Research Grants for research on intractable diseases from the Ministry of Health, Labour and Welfare (MHLW) of Japan (Investigation and Research for Intractable Inflammatory Bowel Disease; Grant Number 20316729).Keywords: Inflammatory bowel disease unclassified, Mediterranean fever gene, Colchicine, Microbiomes Research in context Evidence before this study Inflammatory bowel disease (IBD) includes IBD unclassified (IBDU), which is a subset that does not meet the current diagnostic criteria. Despite this, the pathogenesis of IBDU remains unclear. However, recent findings indicate that patients with IBDU and Mediterranean Fever (MEFV) gene mutations exhibit a positive response to colchicine treatment. In this study, we investigated the frequency of MEFV mutations and evaluated their responsiveness to colchicine in Japanese patients with IBDU. We also investigated the pathogenesis of the disease. Added value of this study This study investigated the clinical features and pathogenesis of colchicine-responsive and MEFV mutation-positive IBDU. Of the 396 patients diagnosed with IBDU, 60.1% (238/396) had MEFV mutations. Patients with IBDU who tested positive for MEFV mutations mainly had exon 2 mutations (83.7%). Among patients with available clinical information, we found that 43.3% of patients with IBDU had typical familial Mediterranean fever. The responsiveness of patients with IBDU carrying MEFV mutations to colchicine treatment was greater >80%. Moreover, enhanced cytokine production by monocytes with MEFV mutations and changes in intestinal microbiota contribute to the pathogenesis of the disease. Implications of all the available evidence This study demonstrated the response of patients with IBDU carrying MEFV mutations to colchicine treatment. The number of patients with IBD has been steadily increasing; however, the primary cause of IBD varies among patients. Therefore, from a therapeutic perspective, IBD, including IBDU, should be categorised according to the MEFV gene or cytokines associated with its pathogenesis. Introduction Inflammasomes are intracellular protein complexes that regulate the production of proinflammatory cytokines through the activation of caspases 1 and 11 in canonical and noncanonical inflammasomes, respectively.1 Caspase-1 subsequently converts its substrates pro-interleukin (IL)-1β and proIL-18 into secreted bioactive cytokines and triggers pyroptosis.1,2 On the other hand, caspase-11 directly mediates pyroptosis and extracellular release of IL-1 α and high mobility group box 1 directly and induces secretion of mature IL-1β and IL-18 indirectly through engagement of the canonical nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3, and inflammasome.3,4 Persistent or prolonged inflammasome activation has been implicated in the development of various autoinflammatory and autoimmune diseases, including neurodegenerative diseases and metabolic disorders.5 Inflammasomes play either causative or contributing roles in the initiation of inflammatory disease and exaggerate the pathology in response to host-derived factors. Among diseases with inflammasomes related to autoinflammatory diseases, familial Mediterranean fever (FMF), a hereditary inflammatory disease characterised by periodic fevers and plasma membrane inflammation, is well recognised. The causative gene of FMF, MEditerranean FeVer (MEFV) responsible for this disease contains 10 exons and 781 codons, which were identified in 1997.6 The clinical presentations are caused by mutations in the MEFV gene that encodes the pyrin protein.7 Although fever, arthritis, and abdominal pain due to peritonitis are the most common symptoms of this disease, intestinal involvement is considered rare because the disease is mainly caused by serositis. In 2012, we reported the case of a patient with inflammatory bowel disease unclassified (IBDU) who had an MEFV mutation and was refractory to 5-aminosalicylic acid and corticosteroid therapy and achieved clinical and endoscopic remission with colchicine alone.8 Since the publication of the abovementioned report, similar papers on the significance of MEFV mutations in patients with IBD have been published.9, 10, 11 These clinical reports suggest the existence of a subset of patients with IBDU and mutated MEFV who show improvement in their colitis with colchicine treatment. This study aimed to elucidate the clinical characteristics and responsiveness to colchicine in Japanese patients with IBDU carrying MEFV mutations. Methods Ethics The study protocol was approved by the Institutional Review Board of Sapporo Medical University (Reference number 282-55) and was publicly registered with the University Hospital Medical Information Network (registration number UMIN000022289). Written informed consent was obtained from all participants before enrolment. Study design In this multicentre retrospective cohort study, we used information obtained from eligible patients in 37 clinical centres between July 19, 2016 and March 31, 2022. Because the clinical characteristics of Japanese patients with IBDU responding to colchicine remain unclear, we initially conducted a cohort study for these patients. Patients We enrolled Japanese patients with enterocolitis who did not meet the current diagnostic criteria for ulcerative colitis (UC) or Crohn's disease (CD) by the research study group on intractable inflammatory bowel disorder of the Ministry of Health, Labour and Welfare in Japan were enrolled.12 Clinical information of enrolled patients We collected the following clinical information of patients: (a) clinical findings (laboratory data, duration of fever, frequency of abdominal attacks, arthritis, skin lesions and neurological findings): (b) endoscopic findings of the oesophagogastroduodenal area, small and large intestines and histological findings: (c) medication taken before starting colchicine: and (d) colchicine responsiveness, which was defined as an improvement in abdominal symptoms (abdominal pain, diarrhoea, and haematochezia) at 2–4 weeks after starting colchicine administration (0.5–1.5 mg/day). MEFV gene analysis Blood samples were collected from all participants in ethylenediatetraacetic acid tubes and DNA was extracted from white blood cells. We analysed the entire exon region (exon 1–10) of MEFV. Polymerase chain reaction (PCR) and sequencing of the MEFV gene: DNA was isolated from peripheral leukocytes using the QIAamp DNA Blood Mini Kit (Qiagen) and the Oragene DNA Self Collection Kits (DNA Genotek). All coding exons and splice junctions, except exon 2 of the MEFV gene, were amplified by PCR in a total volume of 20 μL with 10-mM Tris–HCl, 50-mM KCl, 1.5 mM MgCl2 200 mM of each deoxyribonucleoside triphosphate, and 0.2 mM primers. AmpliTaq Gold (1 U; Roche) and 20 ng genomic DNA were added. Exon 2 was amplified using the GC-RICH PCR System (Roche). PCR reactions were performed on the GeneAmp PCR System 9700 (Applied Biosystems) with denaturation at 94 °C for 10 min, annealing at 60 °C for 30 s, and elongation at 72 °C for 1 min for 35 cycles, and a final elongation at 72 °C for 10 min. Amplicons were purified using ExoSAP-IT and sequenced using an ABI PRISM 3730 (Applied Biosystems). The PCR primer sequences are listed in Supplementary Table S1. The genomic and amino acid sequences of MEFV were collected from the Ensemble: ENSG00000103313 (gene) and ENST00000219596 (transcript). Generation of MEFV-mutated plasmid and its transfection We analysed cytokine production by monocytes with genetic mutations in MEFV by generating mutant MEFV plasmids (predominantly plasmids of exon 2 mutations, which are most frequently observed in enrolled patients). The cDNAs for the MEFV (NM_000243) were amplified using the PCR method with KOD-Plus-Neo Polymerase (TOYOBO, Osaka, Japan) using the reverse transcriptase-PCR products as templates and the primers listed in Supplementary Table S2. The amplified DNA fragment was cloned into a pCR 4 TOPO vector (Invitrogen, Beverly, MA, USA). The pCR4 TOPO MEFV vector was created using the full-length MEFV gene cDNA fragments obtained from THP-1 cells. Using each subcloned vector as a template MEFV DNA, PCR was performed with a MEFV primers containing restriction endonuclease site for EcoRI and Xho 1 (MEFV-Fwd EcoR1: ATAGAATTCATGGCTAAGACCCCTAGTGACC, MEFV-Rev Xho1: TACGCTCGAGGTCAGGCCCCTGACCACCCAC). The PCR products were purified using the Wizard SV Gel and PCR Clean-Up System (Promega, Madison, WS, USA). The MEFV PCR fragment was cloned into the lentiviral plasmid pSF-CMV-NEO-C-3XF (Oxford Genetics) using the EcoR1 and Xho1 restriction enzyme sites to generate the pSFcFLAG MEFV. Using each subcloned vector as a template pSFcFLAG MEFV, PCR was performed with a MEFV primers containing restriction endonuclease sites for EcoRI and Not 1 (MEFV-Fwd EcoR1: ATAGAATTCATGGCTAAGACCCCTAGTGACC, 3xFLAG-Rev Not1: ATGCGGCCGCCTACTTGTCATCGTCATCCTTGTAGTC). pCDH-EF1α-MCS-IRES-Puro (CD532A-2; System Biosciences, Palo Alto, CA, USA), using the EcoR1 and Not1 restriction enzyme sites, were employed to generate the pCDH-MEFV expression plasmid used for lentiviral transduction. These plasmids were co-transfected with packaging plasmids (psPAX2 #12260; Addgene, MA, USA. and pLP/VSVG, Invitrogen) into HEK293T/17 cells to generate a lentivirus that was then used to infect the THP-1 (RRID:CVCL_0006) cells. The viral stocks were incubated with THP-1 cells for 8 h in the presence of 8 μg/mL of polybrene (sc-134220, Santa Cruz Biotechnology, Dallas, TX, USA), followed by addition of fresh media without polybrene. Transduced cells were allowed to proliferate until enough cells were reached for puromycin selection of stable clones expressing MEFV. Cell culture medium was replaced with fresh medium plus 1 μg/mL of puromycin every 2–3 days for 3–4 weeks. The selected MEFV-overexpressing clones were maintained in a puromycin-containing medium for additional experiments. Measurement of cytokine production in THP-1 with exon 2 mutations To analyse the different cytokine production in THP-1 cells with exon 2 mutations and controls, we investigated several cytokines in these activated cells. THP-1 cells (RRID: CVCL_0006) were obtained from American Type Culture Collection (VA, USA: TIB-202) and cultured in suspension in RPMI-1640 (Sigma–Aldrich, STL, USA) with added glutamax and 10% (v/v) foetal bovine serum in a humidified 37 °C, 5% CO2 incubator. All cell culture reagents were purchased from Thermo Fisher Scientific (Waltham, MA, USA). THP-1 cells in the logarithmic growth phase were seeded into 24-well plates (Greiner Bio-One, Kremsmünster Austria) (2.0 × 105 cells per well) and incubated with phorbol 12-myristiate-12 acetate (5 ng/mL Sigma–Aldrich, MO, USA) for 48 h to induce differentiation of THP-1 cells to macrophages. Cells were washed with phosphate-buffered saline and then stimulated with lipopolysaccharide (200 μg/mL NOVUS Biologicals, MN, USA) for 3 h. Subsequently, the cells were stimulated with adenosine triphosphate (5 mM Nacalai Tesque, Kyoto, Japan) for 1 h. After activation, the supernatant was collected and stored at–80 °C until measurement. Cytokine assay: For cytokine measurements, the human inflammation cytometric beads array kit (BD Pharmingen, NJ, USA) was used following the manufacturer's instructions. Analysis of microbiota We analysed the intestinal microbiota of patients with IBDU carrying MEFV mutations, those with IBD (Supplementary Table S3), and healthy controls (Supplementary Table S4). Faecal samples were collected using a brush-type faecal collection kit of with a preservation solution (TechnoSuruga Laboratory, Shizuoka, Japan) and stored at room temperature until measurement. DNA was extracted from the collected faeces using the glass bead extraction method and purified using a previously reported method.13 The V3–V4 region of the 16S rRNA gene was amplified through PCR using barcoded primers, and the PCR products were sequenced using the paired-end technique (Illumina MiSeq platform), as previously described.14 Using the quantitative insights from the microbial ecology tool QIIME 1.8.0),15 8,088,965 high-quality reads were generated and assigned to operational taxonomic units (OTUs). Each OTU was represented by a sequence aligned using the python Nearest Alignment Space Termination16 and classified taxonomically by using UCLUST.17 Microarray analysis of gene change in THP-1 cells with exon 2-mutated plasmid To investigate functional changes in monocytes caused by genetic mutations in MEFV, RNA was extracted from cells transfected with the MEFV-mutant plasmid and controls, and changes in cell surface receptors were comprehensively analysed. RNA-Seq sample preparation: Total RNA was extracted from each sample using an RNeasy Mini Kit (QIAGEN, Valencia, CA, USA). The integrity and quantity of total RNA were measured using an Agilent 2100 Bioanalyzer and an RNA 6000 Nano Kit (Agilent Technologies, Inc., Santa Clara, CA, USA). Library preparation and sequencing: Total RNA obtained from each sample was subjected to sequencing library construction using the TruSeq Stranded mRNA Library Prep Kit (Illumina, Inc., San Diego, CA, USA) following the manufacturer's instructions. The samples were equally pooled and sequenced using a NovaSeq 6000 (Illumina, Inc.) with 101-base-pair (bp) paired-end reads. The process included alignment of the whole transcriptome, quantification of gene expression levels, and detection of differentially expressed genes (DEGs). Sequencing adaptors, low-quality reads, and bases were trimmed using trimmomatic-0.39 tool.18 Sequence reads were aligned to the human reference genome (hg38) using STAR 2.7.9a.19 The aligned reads were subjected to downstream analyses using the StrandNGS software (version 4.0; Agilent Technologies, Inc.). The read counts assigned to each gene and transcript (Ensembl Database 2016.12.01) were quantified using the Transcripts Per Million (TPM) method.20,21 Statistical analyses between two groups (sample and control) were performed using a moderated t-test.22 DEGs were estimated to be significant if the false discovery rate was <0.05 and fold change was >2. Statistics The precise percentage of Japanese patients with IBDU is unknown; however, a report from Europe has indicated that approximately 2.1% of IBD patients are diagnosed with IBDU.23 Given that the total number of IBD patients treated at the participating institutions in this study was approximately 20,000, we set the sample size of the cohort to be approximately 400 patients. The planned sample size was sufficient to provide high precision in binomial statistics, with in a 95% confidence interval half-width of 4.9%, and the actual sample size confers adequate precision, with a 95% confidence interval half-width of 7.2%. No imputations were performed for missing data. To analyse the differences between patients with a single mutation and those with multiple mutations or between patients with homozygosity and those with heterozygosity, normally distributed continuous variables were analysed using the Student's t-test, and non-normally distributed variables were analysed using the Wilcoxon rank-sum test. We assessed the normality of distribution by visually examining histograms and using the Shapiro–Wilk test. For in vitro studies involving cell lines, the Mann–Whitney U test was performed. Categorical variables were analysed using Fisher's exact test. We used non-parametric testing methods, such as the Kruskal–Wallis test and PERMANOVA, for comparing diversity among multiple groups. The metagenomic profiles were analysed using the Wilcoxon rank-sum test. Statistical analyses were performed using JMP Pro 15.1.0 software (SAS Institute Inc., Cary, NC, USA). Hierarchical clustering was performed based on microbiome data (weighted or unweighted, using Ward's method) by R4.2.2. (R Core Team 2022. R: A Language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria). Statistical analyses were performed using the GraphPad Prism (version 8.0: GraphPad Software, MA, USA). Differences were considered statistically significant at p < 0.05. All data are expressed as mean ± standard deviation. Role of funders Funders played no role in the study design; data collection, analysis, interpretation; or writing of the report. Results Characteristics of the patients Of the 396 patients diagnosed with IBDU, 60.1% (238/396) had mutations in the MEFV gene. Of these 238 patients, 190 were investigated, excluding those without endoscopic findings or for whom clinical data were unavailable (Fig. 1). Supplementary Table S5 summarises the details of the proportions of missing data. The median age of the patients with MEFV mutations was 38 years, and 53.7% of the patients were women. Regarding medical history and comorbidities, 7.4% (14/190) of the patients had asthma. Clinical symptoms of patients were abdominal pain in 85.3% (162/190), diarrhoea in 79.5% (151/190), haematochezia in 56.3% (107/190), fever exceeding 38 °C in 55.3% (105/190), arthritis in 36.8% (70/190), neurological findings in 19.5% (37/190), and rash in 13.7% (26/190) (Table 1). Arthritis without joint swelling was most common in the large joints of the knee, wrist, ankle, shoulder, and elbow (Supplementary Figure S1). Laboratory data on diagnosis showed that the median (interquartile range) C-reactive protein and serum amyloid A levels were 0.8 (0.1–4.1) mg/dL and 16.5 (4.0–213.5) mg/L, respectively. Before colchicine use, the use of corticosteroids was 37.0% (64/173), followed by 23.7% (41/173) of tumour necrosis factor (TNF)-α inhibitors and 23.1% (40/173) of azathioprine or 6-mercaptopurine. Some patients were administered a combination of these drugs (Table 1). Other than 56 patients with insufficient information on colchicine responsiveness, we evaluated 134 patients according to the Tel-HaShomer criteria24 and found that the numbers of patients with typical FMF, those with atypical FMF, and those who did not meet the criteria were 43.3% (58/134), 44.0% (59/134), and 12.7% (17/134), respectively (Supplementary Table S6). Flowchart depicting the disposition of cases in the study. Table 1Participants’ demographic characteristics at baseline.Characteristicsn = 190Age (years), median (IQR)38 (25–57)Age at onset (years), median (IQR)30 (20–48.5)Female sex, n (%)102/190 (53.7)Smoking, n (%)29/190 (15.3)Family history, n (%) Ulcerative colitis13/190 (6.8) Crohn's disease11/190 (5.8)Medical history and comorbidities, n (%) Asthma14/190 (7.4) Appendicitis10/190 (5.3) Atopic dermatitis9/190 (4.7) Diabetes8/190 (4.2) Hypertension7/190 (3.7) Drug allergy7/190 (3.7)Clinical symptoms, n (%) Abdominal pain162/190 (85.3) Diarrhoea151/190 (79.5) Haematochezia107/190 (56.3) Fever105/190 (55.3) Arthritis70/190 (36.8) Neurological findings37/190 (19.5) Rash26/190 (13.7) Oral aphtha16/190 (8.4) Anal fistula10/190 (5.3) Chest pain7/190 (3.7) Erythema nodosum7/190 (3.7) Uveitis3/190 (1.6) Back pain2/190 (1.1) Pleuritis2/190 (1.1) Skin nodules1/190 (0.6) Scleritis1/190 (0.6)Laboratory data White blood cell (/μL), median (IQR)7275 (5460–10638) Haemoglobin (g/dL), average ± SD12.3 ± 2.1 Albumin (g/dL), median (IQR)3.8 (3.1–4.3) C-reactive protein (mg/dL), median (IQR)0.8 (0.1–4.1) Serum amyloid A (μg/mL), median (IQR)16.5 (4.0–213.5)Drugs used before starting colchicine, n (%) Prednisolone64/173 (37.0) Anti-TNF-α antibodies41/173 (23.7) Azathioprine/6-mercaptopurine40/173 (23.1) Tacrolimus9/173 (5.2) Ustekinumab8/173 (4.6) Vedolizumab7/173 (4.0) Tofacitinib6/173 (3.5) Methotrexate3/173 (1.7) Tocilizumab1/173 (0.6)IQR: interquartile range, SD: standard deviation. Participants’ demographic characteristics at baseline. IQR: interquartile range, SD: standard deviation. Frequency of MEFV gene-mutation sites and zygosity and the association of their numbers with clinical symptoms Analysis of the site of genetic mutation in patients with IBDU carrying MEFV mutations revealed that exon 2 mutations (83.7%, 150/190) were the most common, followed by exon 3 (20.0%, 38/190), exon 5 (6.8%, 13/190), and exon 1 (4.7%, 9/190) mutations (Fig. 2a). Among exon 2 mutations, the frequency of E148Q (65.3%, 124/190) was highest, followed by L110P (23.7%, 45/190), R202Q (11.6%, 22/190), and G304R (9.5%, 18/190) (Fig. 2b). Sites of MEFV mutation in patients with IBDU (a), and the frequency of MEFV mutations among exon 2 mutations in patients with IBDU (b). IBDU: inflammatory bowel disease unclassified, MEFV: MEditerranean FeVer. The proportions of patients with a single mutation and multiple mutations were 53.2% (101/190) and 46.8% (89/190), respectively. Among patients with multiple mutations, the proportions of patients with two, three, four, and six mutations were 35.8% (68/190), 7.9% (15/190), 2.6% (5/190), and 0.5% (1/190), respectively. The frequencies of patients with homozygosity, homo/heterozygosity, and heterozygosity were 22.6% (43/190), 12.1% (23/190), and 65.3% (124/190), respectively (Supplementary Table S7). Supplementary Tables S8 and S9 show the differences in clinical symptoms and laboratory data between patients with a single mutation and those with multiple mutations or between patients with homozygosity and those with heterozygosity. Supplementary Table S10 shows sex differences in clinical symptoms, laboratory data, and frequency of MEFV mutation. Characteristics of endoscopic findings and association between the mutation sites and the distribution of gastrointestinal lesions Endoscopic findings revealed lesions in all gastrointestinal tracts. The most frequent site of lesions was the colon (86.3%), followed by the jejunum (52.5%) and then the terminal ileum (45.4%). The distribution of colonic lesions was 51.2% (83/162) in the entire colon, 24.7% (40/162) limited to the right-sided colon, and 24.1% (39/162) limited to the left-sided colon. In addition, 39.8% (64/161) of the patients did not have rectal lesions (Table 2). The endoscopic findings at all gastrointestinal sites varied, with irregularly shaped ulcers, aphtha, erosions, longitudinal ulcers, and pseudopolyposis. Representative endoscopic findings and their frequencies are shown in Fig. 3. Histological examination did not reveal any characteristic findings of these enterocolitis. Table 2Site of endoscopic findings.Endoscopic findingsn = 190Site of gastrointestinal lesions, n (%) Oesophagus11/153 (7.2) Stomach59/153 (38.6) Duodenum46/153 (30.1) Jejunum/ileum62/118 (52.5) Terminal ileum84/185 (45.4) Colon164/190 (86.3)Distribution of colonic lesions—No. (%) Entire colon83/162 (51.2) Limited to the right-sided colon40/162 (24.7) Limited to the left-sided colon39/162 (24.1) Spared rectal lesions, n (%)64/161 (39.8) Site of endoscopic findings. Endoscopic findings in patients with IBDU carrying MEFV mutations. Oesophagogastroduodenal lesions (a), small intestinal lesions (b), and colonic lesions (c). IBDU: inflammatory bowel disease unclassified, MEFV: MEditerranean FeVer. Among several mutations, exon 2 had the highest mutation frequency among the enrolled patients. Therefore, we examined the association between the mutation sites in exon 2 and the distribution of gastrointestinal lesions, but we did not find any mutation site-specific gastrointestinal lesions (Supplementary Figure S2). Furthermore, there was no evidence of an association of the number of mutations and zygosity of MEFV genes with the location of the gastrointestinal lesions. Effectiveness of colchicine in patients with IBDU carrying MEFV mutations Colchicine was administered to 138 of the 190 patients. Excluding the 15 patients for whom the effectiveness of treatment could not be determined, the treatment response rate was 84.6% (104/123) (Table 3). Table 3Effectiveness of colchicine in patients with IBDU carrying MEFV mutations.Effectiveness of colchicine on patients with IBDU carrying MEFV mutations Colchicine was administered, n (%)138/190 (72.6) Effectiveness of treatment could be determined, n123 Response to treatment, n (%)104/123 (84.6)Effectiveness of treatment could not be determined, n.15 Discontinued due to side effects4 Unable to assess effectiveness owing to the short treatment period9 Unknown efficacy2 Effectiveness of colchicine in patients with IBDU carrying MEFV mutations. Difference in cytokine production and surface markers between exon 2-mutated THP-1 cells and THP-1 cells Most MEFV mutations in patients with IBDU carrying MEFV mutations were in exon 2. Therefore, we focused on the plasmids generating exon 2 mutations (c. 329T > C, p. Leu110Pro, c. 442C > C, p. Glu148Gln, c. 605G > A, p. Arg202Gln, c. 910G > A, and p. Gly304Arg) and transfected them into THP-1 cells to examine the effect of each mutation on cytokine production. On stimulation with phorbol 12-myristate 13-acetate (PMA) and lipopolysaccharide (LPS), THP-1 cells transfected with exon 2 mutation plasmids produced significantly higher levels of IL-1β, TNF-α, IL-6, and IL-8 than controls (Fig. 4). However, there was no significant difference in IL-10 production between exon 2-mutated THP-1 and wild-type cells. Cytokine production from THP-1 cells transfected with exon 2 mutation plasmids after differentiation with phorbol 12-myristate 13-acetate and stimulation with lipopolysaccharide plus adenosine triphosphate. CI: confidence interval, IL: interleukin, TNF: tumour necrosis factor. Microarray analysis demonstrated that the expression of several cell surface receptors (ADAMTS15, AXL, CD86, ITGA7, NLGN2, ASIC1, and TNFRSF11A) was significantly upregulated in MEFV gene-mutated cells compared to that of controls (Supplementary Figure S3). Difference in faecal microbiota between patients with IBDU carrying MEFV mutations and healthy controls We also found significant differences in α-diversity (Shannon index) and β-diversity (unweighted) of faecal microbiota between patients with IBDU carrying MEFV mutations and healthy controls (Fig. 5a). Hierarchical clustering demonstrated a visually distinct pattern. Similar findings were observed in patients with IBDU carrying MEFV mutations and in those with IBD (Fig. 5b). However, no significant difference was noted in α-diversity between patients with IBDU carrying MEFV mutations who complained of FMF-related symptoms including abdominal symptoms and who did not (Fig. 5c). The metagenomic profiles that were analysed revealed that the expression of Escherichia-Shigella, Ruminococcus (gnavus_group), Streptococcus, Enterococcus, and Veillonella at the genus level was significantly increased in patients with IBDU carrying MEFV mutations compared with that in healthy controls. Furthermore, the expression of Phascolarctobacterium, Eubacterium_hallii_group, Dorea, Parabacteroides, Alistipes, and Ruminococcus_torques_group, at the genus level was significantly increased in patients with IBDU carrying MEFV mutations compared with that in patients with IBD. An increased tendency of Streptococcus and Klebsiella was observed in patients with IBDU carrying MEFV mutations compared with that in patients with IBD (Fig. 5d and e). Microbiome analysis. Differences in the α-and β-diversity and hierarchical clustering of gut microbiota (a) between patients with IBDU carrying MEFV mutations and healthy controls and (b) between patients with IBDU carrying MEFV mutations and those with IBD. (c) Differences in α-diversity between patients with IBDU carrying MEFV mutations who complained of FMF-related symptoms including abdominal symptoms and those who did not. Phylogenetic tree highlighting abundant gut microbiota and metagenomic profiles at genus level (d) between patients with IBDU carrying MEFV mutation and healthy controls and (e) between patients with IBDU carrying MEFV mutations and those with IBD. IBD: inflammatory bowel disease, IBDU: inflammatory bowel disease unclassified, MEFV: MEditerranean FeVer. Discussion In this retrospective study, we investigated the clinical characteristics of patients with IBDU carrying MEFV mutations and their response to colchicine treatment, and we elucidated the pathogenesis of these mutations. First, 60.1% of patients with IBDU had mutations in the MEFV gene, and these patients mainly had exon 2 mutations (83.7%). Based on the clinical data of patients, we found that 43.3% of patients with IBDU had typical FMF, whereas 44.0% showed atypical FMF. These data strongly indicate that patients with FMF may have accompanying enterocolitis and patients with IBDU may have pyrin-associated autoinflammation. Next, we investigated the effect of colchicine on patients with IBDU carrying MEFV mutations and found that the response to treatment was 84.6%. Considering the response ratio, patients with IBDU carrying MEFV mutations should be distinguished from patients with UC and CD diagnosed according to the current diagnostic criteria. Regarding the mechanism in patients with IBDU carrying MEFV mutations, enhanced inflammatory cytokine production by MEFV gene-mutated THP-1 cells and microbiome changes in patients with IBDU carrying MEFV mutations, which differ from healthy controls despite the disease activities, suggest that the microbiome changes might trigger MEFV-related enterocolitis. Previous studies have suggested the involvement of inflammasome activation through external and internal factors in the development of various inflammatory diseases, one of which is FMF, whose responsible gene is the MEFV coding pyrin protein that negatively regulates inflammasome activity by inhibiting the binding of apoptosis-associated speck-like protein containing caspase recruitment domain and caspase 1.25,26 Persistence of inflammation due to dysfunction of pyrin is considered to be a pathological condition of FMF.27 This disease itself is of autosomal recessive inheritance, and patients generally have a mutant MEFV homozygote or a compound heterozygote.28, 29, 30, 31 However, cases of typical FMF patients with MEFV heterozygous mutations have also been reported.32,33 The accompanying symptoms in patients with FMF differ depending on race and diverse variant alleles of MEFV.34,35 Thus, these data indicate an unknown pathogenic role of the MEFV gene. Recently, MEFV mutations in patients with enterocolitis have been reported to drastically respond to colchicine.8, 9, 10, 11 However, to the best of our knowledge, no large studies have reported the complications of intestinal inflammation with endoscopic findings in patients with FMF or MEFV mutations. Therefore, the mechanism by which MEFV mutations contribute to intestinal inflammation remains unclear. Endoscopic findings vary widely.8,9 In our study, lesions were predominantly found in the large intestine, followed by the jejunum and terminal ileum. The distribution of lesions in the small intestine may differ from that in patients with CD.10 We found no disease-specific endoscopic findings. These heterogeneous endoscopic findings may be a feature of intestinal inflammation caused by autoinflammatory diseases. Future approaches to distinguish between patients with IBDU carrying MEFV mutations and those with IBD will require molecular biology approaches, such as the differential expression of cytokines at the site of intestinal inflammation in addition to morphological features. Our study findings revealed that mutations in exon 2 are common in patients with IBDU similar to previous reports of Japanese patients with FMF.36 Regarding the significance of exon 2 mutations, it is still unclear whether they are causative gene mutations. Meanwhile, a previous study has reported that the combination of exon 2 (in particular, E148Q) with other MEFV mutations contributes to disease exacerbation.37 Comprehensive analysis of surface markers in THP-1 cells transfected with the mutant plasmid showed that exon 2-mutated THP-1 cells exhibited an activated state with enhanced expressions of CD86, TNFRSF11A and AXL compared to wild-type cells. Thus, our in vitro data indicate that patients with exon 2 mutations are prone to inflammation. Considering people with exon 2 mutations who do not necessarily have FMF symptoms, our data suggest that external factors play a significant role in determining whether exon 2 mutations play a pathogenic or a disease-modifying roles. Previous research has reported the involvement of dysbiosis in the development of various diseases.38 Therefore, we also compared the intestinal microbiota of patients with IBDU carrying MEFV mutations, patients with IBD, and healthy controls. We found that the intestinal microbiota pattern of patients with IBDU carrying MEFV mutations differed from that of patients with IBD and healthy controls. In addition, despite disease activity, no change was noted in the pattern of gut microbiota in patients with IBDU carrying MEFV mutations despite their disease activities. These data indicate that, as in other chronic inflammatory diseases, changes in the gut microbiota may trigger the development of the disease. The present metagenomic analysis allowed us to identify bacteria at the genus level that showed significant increases in patients with IBDU carrying MEFV mutations compared to healthy controls and patients with IBD, suggesting that patients with IBDU carrying MEFV mutations have many mucin-degrading bacteria and those associated with the onset of multiple sclerosis. The higher prevalence of Streptococcus in patients with IBDU carrying MEFV mutations than in patients with IBD and healthy controls is a characteristic feature. Recent reports have demonstrated that Streptococcus intermedius and Streptococcus anginosus are involved in the development of systemic lupus erythematosus.39 Thus, the Streptococcus genus may contribute to the development of autoimmune diseases, including FMF and MEFV-related enterocolitis. Based on these data, the role of Streptococcus in MEFV gene-associated intestinal lesions should be elucidated using a gnotobiotic system in the future. Several reports have mentioned the role of the MEFV gene in IBD pathology; Papadopoulos et al. performed a meta-analysis of the MEFV gene in IBD patients and found that the MEFV mutation rate in IBD patients was 0.238 (95% CI: 0.209–0.270; I2 = 95%) and MEFV-mutated alleles were more frequent in IBD patients than in controls.10 Subgroup analysis revealed that an increase in MEFV mutations in patients with IBDU compared with those with UC and CD. Amaryan et al. reported that in untreated IBD patients under 18 years of age, the frequency of FMF was 36.2% (25/69), and MEFV mutations were identified in 53.6% (37/69). Patients with UC had the highest rates of MEFV mutations and FMF (61.1% and 41.6%, respectively). Additionally, 56.7% (21/37) of patients with IBD carrying MEFV mutations had M694V-mutated alleles.40 Furthermore, we examined the significance of MEFV mutations in CD patients; Japanese patients with CD carrying the Exon2 E148Q mutation had more refractory stenosis and fistula than those without the mutation.11 Microbiome studies in patients with FMF reported a reduction in gut bacterial diversity during attacks of patients with FMF, with major shifts in bacterial populations within the Firmicutes, Bacteroidetes, and Proteobacteria phyla.41,42 The results of studies combining MEFV mutations and gut microbiota analysis suggest that changes in the gut microbiota may be influenced by the host-specific genetic variation.41, 42, 43 Importantly, the frequency of MEFV mutation sites varies from region to region, and differences in clinical symptoms and activity are observed depending on the mutation site. This suggests that the bacterial flora that contributes to disease onset and exacerbation may differ in patients with Exon 2 and Exon 10 mutations. The results underscore the need to consider the influence of environmental factors, including gut bacteria, in MEFV-related diseases. Furthermore, our findings suggest that MEFV mutations not only contribute to the development of autoinflammatory diseases, such as FMF but also have the potential to significantly alter the pathogenesis of other inflammatory diseases, which is a possibility that warrants further investigation. This study has some limitations. First, the analysis was based on limited data because not all patient clinical information was available. Despite the lack of clinical information in some cases, they were sufficient to examine the clinical characteristics of patients with IBDU carrying MEFV mutations. Second, histological evaluation of intestinal tissue in patients with IBDU carrying MEFV mutations was limited. Therefore, accumulating histological examinations results in the future could obtain characteristic findings in histology for diagnosing MEFV gene-associated intestinal lesions. Lastly, we did not investigate the frequency of MEFV mutations in Japanese patients with IBD diagnosed according to the current diagnostic criteria; therefore, this should be considered in future studies to determine whether patients with IBD can be successfully treated with colchicine. In conclusion, we demonstrated the existence of patients with IBDU carrying MEFV mutations who responded drastically to colchicine treatment. The number of patients with IBD has been steadily increasing; however, the main causes of IBD differ in each patient. Therefore, IBD, including IBDU, should be categorised by the cytokines that are associated with pathogenesis from a therapeutic perspective. In the future, MEFV gene-associated enterocolitis may be renamed IL-1β-related enterocolitis. Finally, the characteristics of patients with MEFV gene-associated intestinal inflammation will become more evident with the accumulation of more cases. Contributors HN, KW, TK, TM, ME, KW, RK, TT, KA, TI, DI, YM, HS, NU, KY, MS, RH, JY, and TH participated in data acquisition; HN, KW, TK, TM, ME, and TH participated in study design; HN, KW, TK, TM, ME, and TH assessed and verified the data; and HN, KW, TK, ST, and MN participated in statistical analysis. All authors had access to relevant data and participated in data interpretation, critically reviewed the manuscript, and provided final approval for publication. The MEFV-IBDU Group member contributed to the enrolment of participants in this study. A complete list of the MEFV-IBDU group is provided in the Supplementary Consortia. The members did not receive honoraria, or payments for authorship. Data sharing statement Raw data were generated at the Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine. The datasets from this study in online repositories are available from the corresponding author, HN, upon reasonable request with proposals. The metagenomic data of human intestinal microbiota obtained from fecal samples have been deposited in the DDBJ BioProject database, with links to BioProject accession number PRJDB18583. Declaration of interests Dr Hiroshi Nakase (HN) reports receiving personal fees from Abbvie Inc., Kissei Pharmaceutical Co., Ltd., KYORIN Pharmaceutical Co., Ltd, Mitsubishi Tanabe Pharma Corporation, Janssen Pharmaceutical K.K, Takeda Pharmaceutical Co., Ltd., Pfizer Japan Inc., EA Pharma Co., Ltd., Mochida Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Gilead Sciences Inc., VIATRIS Inc., JIMRO Co., Ltd., and grants for commissioned/joint research from Hoya Group Pentax Medical, Mitsubishi Tanabe Pharma Corporation, Mochida Pharmaceutical Co., Ltd., and Abbvie Inc. He has endowed chair by Miyarisan Pharmaceutical Co., Mochida Pharmaceutical Co., Ltd. JIMRO Co., Ltd., and KYORIN Pharmaceutical Co., Ltd. Dr Taku Kobayashi (TK) served as an advisory board member, consultant, or speaker for AbbVie, Activaid, Alfresa Pharma, Alimentiv, Bristol Myers Squibb, Celltrion, Covidien, EA Pharma, Eli Lilly, Ferring Pharmaceuticals, Galapagos, Gilead Sciences, Janssen Pharmaceuticals, JIMRO, Kissei Pharmaceutical, Kyorin Pharmaceutical, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Nippon Kayaku, Pfizer, Takeda, and Zeria Pharmaceutical, and has received research funding from AbbVie, Alfresa Pharma, Bristol Myers Squibb, EA Pharma, Gilead Sciences, Kyorin Pharmaceutical, Mochida Pharmaceutical, Nippon Kayaku, Otsuka Holdings, Pfizer, Sekisui Medical, Takeda, and Zeria Pharmaceutical. Dr Takayuki Matsumoto (TM) reports receiving personal fees from Abbvie Inc., Kissei Pharmaceutical Co., Ltd., KYORIN Pharmaceutical Co., Ltd, Mitsubishi Tanabe Pharma Corporation, Janssen Pharmaceutical K.K, Takeda Pharmaceutical Co., Ltd., Pfizer Japan Inc., EA Pharma Co., Ltd., Mochida Pharmaceutical Co., Ltd., Gilead Sciences Inc., VIATRIS Inc., JIMRO Co., Ltd. Dr Motohiro Esaki (ME) reports receiving personal lecture fees from AbbVie GK, Mitsubishi Tanabe Pharma, EA Pharma Co., Ltd., Janssen Pharmaceutical; Takeda Pharmaceuticals, Pfizer Japan Inc., Gilead Sciences Inc., research grants from Alfresa Pharma Corporation, and scholarship donation from Pfizer Japan Inc. and KYORIN Pharmaceutical Co., Ltd. Dr Kenji Watanabe (KW) reports receiving research support or contract of clinical trial from EA Pharma Co., Ltd., Takeda Pharmaceutical Co., Ltd., and AbbVie Japan Co., Ltd., and JIMRO Co., Ltd. He reports receiving payment for consulting, lectures, presentations, educational events, or expert testimony from EA Pharma Co., Ltd., AbbVie Japan Co., Ltd., Takeda Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., and Kissei Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Kyorin Pharmaceutical Co., Ltd., JIMRO Co., Ltd., Mochida Pharmaceutical Co., Ltd., Pfizer Japan Inc., Zeria Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd, and support for attending meetings from EA Pharma Co., Ltd., AbbVie Japan Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., JIMRO Co., Ltd., Mochida Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., Pfizer Japan Inc., Zeria Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd, Kissei Pharmaceutical Co., Ltd., and Olympus Corporation. He reports participating on data safety monitoring board or advisory board for EA Pharma Co., Ltd., Takeda Pharmaceutical Co., Ltd., AbbVie Japan Co., Ltd., Janssen Pharmaceutical K.K., JIMRO Co., Ltd., Mochida Pharmaceutical Co., Ltd., and Kissei Pharmaceutical Co., Ltd. and receiving medical writing from Takeda Pharmaceutical Co., Ltd., Pfizer Inc., and AbbVie Japan Co., Ltd., and trial use of endoscopic equipment from Olympus Corporation. Dr Reiko Kunisaki (RK) reports receiving personal fees from Abbvie Inc., EA Pharma Co., Ltd., Janssen Pharmaceutical K.K, JIMRO Co., Ltd, KYORIN Pharmaceutical Co., Ltd, Nippon Kayaku Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Takeda Pharma Co Ltd, and grants for commissioned/joint research from Abbvie Inc., EA Pharma Co., Ltd., Eli Lill Japan, Janssen Pharmaceutical K.K, JIMRO Co., Ltd, Takeda Pharma Co Ltd, Viatris Inc, VectivBio, outside the submitted work. Dr Katsuhiro Arai (KA) reports receiving grants support from Janssen Pharmaceutical K.K., Bristol-Myers Squibb Company, Eli Lilly Japan K.K., Takeda Pharmaceutical CO., Ltd., Pfizer Inc., and Zeria Pharmaceutical Co., Ltd., and consulting fees from EA Pharma Co., Ltd., AbbVie GK, Takeda Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., and Zeria Pharmaceutical Co., Ltd., and honoraria for lecture from AbbVie GK, EA Pharma Co., Ltd., Nobelpharma Co., Ltd., Takeda Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Co., Ltd., Miyarisan Pharmaceutical Co., Ltd., Kissei Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., and Chugai Pharmaceutical Co., Ltd. Dr Dai Ishikawa (DI) reports receiving personal lecture fees from AbbVie GK, EA Pharma Co., Ltd., Zeria Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Co., Ltd., Miyarisan Pharmaceutical Co., Ltd., Kissei Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., and Pfizer Japan Inc. Dr Yuichi Matsuno (YM) reports receiving personal lecture fees from Mitsubishi Tanabe Pharma, Mochida Pharmaceutical Co., Ltd. Dr Hirotake Sakuraba (HS) receiving personal fees from AbbVie Inc., Takeda Pharmaceutical Co., Ltd, Janssen Pharmaceutical K.K., Pfizer Japan Inc., Mitsubishi Tanabe Pharma Factory Ltd., Eisai Co., Ltd, Nippon Kayaku Co., Ltd, EA Pharma Co., Ltd., and research grants from Yakult Honsha Co., Ltd, LAVIEPRE Co., Ltd, Kao Corporation, Bristol-Myers Squibb Company, AbbVie Inc., AsahiKASEI Pharma Co., Ltd. Dr Nobuhiro Ueno (NU) reports receiving educational grant support from Pfizer Inc. Dr Kaoru Yokoyama (KY) reports receiving personal fees from Abbvie Inc., EA Pharma Co., Ltd., Gilead Sciences Inc. and Takeda Pharmaceutical Co., Ltd. Dr Masayuki Saruta (MS) received scholarship grants form Abbvie GK, EPS Corporation, Zeria Pharmaceutical Co., Ltd, Mochida Pharmaceutical Co., Ltd, EA Pharma Co., Ltd, Kissei Pharmaceutical Co., Ltd, CMIC CMO Co., Ltd., PPD-SNBL K.K. and lecture fees from Abbvie GK, Janssen Pharma K.K., Mitsubishi Tanabe Pharma, Takeda Pharmaceutical Co., Ltd., Kissei Pharmaceutical Co., Ltd, EA Pharma Co., Ltd, Gilead Sciences K.K., Mochida Pharmaceutical Co., Ltd, Viatris Pharmaceutical Co., Ltd., Nobelpharma Co., Ltd. Dr Masanori Nojima (MN) reports receiving consulting fees from Chugai Pharmaceutical Co., Ltd., JIMRO Co. Ltd., and Alfresa Pharma Corporation, and honoraria for lectures from EA pharma Co. Ltd., Eisai Co., Ltd., and JIMRO Co. Ltd. Dr Tadakazu Hisamatsu (TH) reports jointing research of EA pharma Co. Ltd., and Kissei Pharmaceutical Co. Ltd., and receiving grants support from Mitsubishi Tanabe Pharma Corporation, AbbVie GK, JIMRO Co. Ltd., Zeria Pharmaceutical Co. Ltd., Kyorin Pharmaceutical Co. Ltd., Nippon Kayaku Co. Ltd., Takeda Pharmaceutical Co. Ltd., Pfizer Inc., Mochida Pharmaceutical Co. Ltd., and Boston Scientific Corporation, and consulting fees from Mitsubishi Tanabe Pharma Corporation, EA pharma Co. Ltd., AbbVie GK, Janssen Pharmaceutical K.K., Pfizer Inc., Nichi-Iko Pharmaceutical Co. Ltd., Eli Lilly, Gilead Sciences, Bristol Myers Squibb, and Takeda Pharmaceutical Co. Ltd., and honoraria for lectures from Mitsubishi Tanabe Pharma Corporation, EA pharma Co. Ltd., AbbVie GK, Janssen Pharmaceutical K.K., Pfizer Inc., Nichi-Iko Pharmaceutical Co. Ltd., Eli Lilly, Gilead Sciences, Bristol Myers Squibb, Mochida Pharmaceutical Co., Ltd., JIMRO Co. Ltd., and Takeda Pharmaceutical Co. Ltd. Dr. Kohei Wagatsuma (KH), Teruyuki Takeda (TT), Takashi Ibuka (TI), Ryota Hokari (RH), Junji Yokoyama (JK), and Shu Tamano (ST) reports no relevant conflicts of interest for this article. Acknowledgements This work was supported by the Japan Agency for Medical Research and Development (21ek0410057h0003), a grant from the Uehara Memorial Foundation, and the Health and Labour Sciences Research Grants for research on intractable diseases from the Ministry of Health, Labour and Welfare (MHLW) of Japan (Investigation and Research for Intractable Inflammatory Bowel Disease; Grant Number 20316729). Footnotes Supplementary data related to this article can be found at https://doi.org/10.1016/j.ebiom.2024.105454. Contributor Information Hiroshi Nakase, Email: hiropynakase@gmail.com. MEFV-IBDU Group: Shusaku Yoshikawa, Sohachi Nanjo, Akira Andoh, Takeshi Kimura, Makoto Ooi, Ryosuke Kiyomori, Nobuo Aoyama, Fumihito Hirai, Atsushi Yamaushi, Masanao Nakamura, Fumikazu Koyama, Shuhei Hosomi, Kazuki Kakimoto, Satoshi Motoya, Ryosuke Sakemi, Hideo Suzuki, Tadashi Hosoya, Ken Takeuchi, Manabu Shiraki, Hideyuki Koide, Ichiro Takeuchi, Yosuke Furui, Kento Yoshida, Ayaka Minemura, Asami Matsumoto, and Kentaro Oka Supplementary data Consortia members MEFV Supplementary Tables 2024 MEFV Research Protocol Supplementary Figure S1 Joint pain and swelling (n = 56). Supplementary Figure S2 The association between MEFV mutation sites of exon 2 and distribution of gastrointestinal lesions. Supplementary Figure S3 Gene expression profiling in MEFV-mutated THP-1 cells by microarray analysis. References Associated Data Supplementary Materials Consortia members MEFV Supplementary Tables 2024 MEFV Research Protocol Supplementary Figure S1 Joint pain and swelling (n = 56). Supplementary Figure S2 The association between MEFV mutation sites of exon 2 and distribution of gastrointestinal lesions. Supplementary Figure S3 Gene expression profiling in MEFV-mutated THP-1 cells by microarray analysis.